SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin - Quaterly Results

18 May 2022 Evaluate
The revenue zoomed 13.49% to Rs. 28553.90 millions for the quarter ended March 2022 as compared to Rs. 25159.60 millions during the corresponding quarter last year.The Net Loss for the quarter ended March 2022 is Rs. -358.90 millions as compared to Net Profit of Rs. 3163.60 millions of corresponding quarter ended March 2021Operating profit for the quarter ended March 2022 rose to 5171.50 millions as compared to 4911.20 millions of corresponding quarter ended March 2021.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 28553.90 25159.60 13.49 117716.70 110559.30 6.47 117716.70 110559.30 6.47
Other Income 570.30 660.70 -13.68 2169.90 1290.90 68.09 2169.90 1290.90 68.09
PBIDT 5171.50 4911.20 5.30 4261.30 21731.50 -80.39 4261.30 21731.50 -80.39
Interest 245.80 123.10 99.68 734.70 406.20 80.87 734.70 406.20 80.87
PBDT 4925.70 4788.10 2.87 3526.60 21325.30 -83.46 3526.60 21325.30 -83.46
Depreciation 1310.20 1250.10 4.81 5141.90 5028.30 2.26 5141.90 5028.30 2.26
PBT 3615.50 3538.00 2.19 -1615.30 16297.00 -109.91 -1615.30 16297.00 -109.91
TAX 3974.40 374.40 961.54 271.70 3710.80 -92.68 271.70 3710.80 -92.68
Deferred Tax 3419.40 236.70 1344.61 -306.30 82.30 -472.17 -306.30 82.30 -472.17
PAT -358.90 3163.60 -111.34 -1887.00 12586.20 -114.99 -1887.00 12586.20 -114.99
Equity 909.00 907.40 0.18 909.00 907.40 0.18 909.00 907.40 0.18
PBIDTM(%) 18.11 19.52 -7.22 3.62 19.66 -81.58 3.62 19.66 -81.58

Lupin Share Price

2476.10 77.40 (3.23%)
03-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1904.65
Dr. Reddys Labs. 1374.55
Cipla 1458.45
Zydus Lifesciences 1141.00
Lupin 2476.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: